Central Post-Stroke Pain Syndrome

Treat abrupt new focal deficits, acute severe headache, altered consciousness, fever with meningismus, or rapidly escalating pain as a possible new cerebrovascular, infectious, or other structural event rather than established CPSP. Obtain urgent neuroimaging when the clinical change raises concern for new stroke, hemorrhage, or another intracranial lesion; prior stroke does not make subsequent symptoms attributable to chronic central pain. CT or MRI is also required to document the original lesion's type, location, and size when establishing CPSP. ScienceDirect+1ScienceDirectReview Central post-stroke pain: clinical characteristics, ...CDCCDC Guideline for Prescribing Opioids for Chronic Pain

CPSP results from stroke-related damage to the central somatosensory nervous system and may arise from lesions beyond the thalamus; avoid restricting the diagnosis to the historical term thalamic pain. Symptoms commonly begin 3 to 6 months after stroke, although onset is variable. The clinical consequence is a delay-prone diagnosis in patients whose pain appears after the acute rehabilitation period. AHA Journals+1AHA JournalsPathophysiology of Central Poststroke Pain | StrokePubMedCentral Post-Stroke Pain Syndrome - StatPearls - NCBI - NIH

Ask the patient to map the painful territory relative to the stroke deficits, then examine pinprick, temperature, light touch, vibration, proprioception, and evoked pain in the painful and contralateral homologous areas. A lesion-concordant distribution with sensory loss, dysesthesia, allodynia, or hyperalgesia supports central neuropathic pain; a normal or mechanically localized examination should redirect the workup toward a nociceptive, peripheral nerve, or regional pain syndrome. ScienceDirect+1ScienceDirectReview Central post-stroke pain: clinical characteristics, ...PubMedCentral Post-Stroke Pain Syndrome - StatPearls - NCBI - NIH

Confirm the cerebrovascular lesion on CT or MRI, then determine whether the lesion plausibly involves central somatosensory pathways relevant to the painful territory. Imaging supports causal attribution and excludes alternative intracranial pathology, but imaging alone does not diagnose CPSP because pain after stroke often has mixed causes. ScienceDirect+1ScienceDirectReview Central post-stroke pain: clinical characteristics, ...AHA JournalsPrevalence, Trajectory, and Predictors of Poststroke Pain

Use a structured sensory examination rather than symptom labels alone. Compare painful with nonpainful regions for hypoesthesia, hyperalgesia, dynamic mechanical allodynia, and cold-evoked pain. Quantitative sensory testing and somatosensory evoked potentials can characterize sensory abnormalities, but the core diagnostic approach remains history, clinical sensory examination, and lesion imaging. ScienceDirectScienceDirectReview Central post-stroke pain: clinical characteristics, ...

Actively search for coexisting pain mechanisms at each reassessment. A patient may have CPSP plus spasticity, shoulder subluxation, contracture, or shoulder-hand syndrome; failure of a neuropathic agent may therefore indicate an untreated second generator rather than absence of CPSP. AHA Journals+2AHA JournalsPrevalence, Trajectory, and Predictors of Poststroke PainWolters KluwerAcupuncture for shoulder-hand syndrome after stroke: An... : MedicinePubMedCentral Post-Stroke Pain Syndrome - StatPearls - NCBI - NIH

Amitriptyline has randomized-trial evidence in CPSP, with pain-intensity reduction reported during the fourth and final treatment week in a controlled trial. Consider it when sleep disturbance coexists, but weigh anticholinergic burden, sedation, orthostasis, and cardiac risk against expected benefit, particularly in older stroke survivors. AHA Journals+2AHA JournalsManagement of Central Poststroke Pain | StrokeAHA JournalsSome Painful News about Central Post-Stroke Pain | AHA BlogsPubMedClinical use of pregabalin in the management of central neuropathic pain - PMC

Lamotrigine reduced CPSP and cold allodynia at 200 mg/day in a controlled study. Its role is most useful when an oral alternative to a tricyclic is needed; titrate cautiously and stop for a clinically concerning rash because dose escalation is constrained by cutaneous toxicity risk. PubMedPubMedClinical use of pregabalin in the management of central neuropathic pain - PMC

Pregabalin and gabapentin are established options for central neuropathic pain, although large-scale CPSP trials remain limited. For pregabalin, a cited regimen is 75 mg once or twice daily initially, with increase to 300 mg/day within 1 week based on efficacy and tolerability; selected patients may require a lower 25 mg starting dose and slower escalation after stroke. Adjust pregabalin for renal impairment. Wiley+1WileyPharmacotherapies for Central Post‐Stroke Pain: A ...PubMedClinical use of pregabalin in the management of central neuropathic pain - PMC

For patients with creatinine clearance of at least 60 mL/min, pregabalin dosing cited for central neuropathic pain is 75 to 150 mg twice daily or 50 to 100 mg three times daily; doses may be increased to 600 mg/day after a further 2 to 4 weeks when benefit and tolerability justify escalation. Reassess dizziness, somnolence, edema, gait safety, and functional effect during titration, especially when the patient already has post-stroke fall risk. PubMedPubMedClinical use of pregabalin in the management of central neuropathic pain - PMC

Avoid treating CPSP as an opioid-responsive nociceptive syndrome. Long-term opioid treatment has been associated with worse outcomes than short-term treatment in a population-based neuropathic-pain cohort, and chronic opioid prescribing guidance emphasizes confirming the diagnosis and addressing disease-specific and nonpharmacologic interventions. Reserve any opioid decision for exceptional circumstances with explicit reassessment of benefit, harms, and alternatives. Nature+1NatureNeuropathic pain | Nature Reviews NeurologyCDCCDC Guideline for Prescribing Opioids for Chronic Pain

Before labeling CPSP refractory, repeat the lesion-concordance and sensory assessment, review adherence and dose-limiting adverse effects, and identify untreated spasticity, shoulder pathology, contracture, or shoulder-hand syndrome. This step is essential because several post-stroke pain syndromes frequently coexist and a central analgesic will not resolve a mechanical or regional limb process. AHA Journals+2AHA JournalsPrevalence, Trajectory, and Predictors of Poststroke PainWolters KluwerAcupuncture for shoulder-hand syndrome after stroke: An... : MedicinePubMedCentral Post-Stroke Pain Syndrome - StatPearls - NCBI - NIH

Integrate physical therapy and psychologically informed pain care when pain limits mobility, limb use, sleep, or rehabilitation participation. Stretching and exercise may help functional impairment, although empirical evidence is limited; use therapy to preserve movement and address the noncentral components of post-stroke pain rather than presenting it as a replacement for lesion-directed neuropathic pain treatment. PubMedPubMedCentral Post-Stroke Pain Syndrome - StatPearls - NCBI - NIH

Consider referral for noninvasive neuromodulation when medication trials are inadequate or poorly tolerated and pain remains function-limiting. A 2024 systematic review and meta-analysis of randomized CPSP trials reported moderate pain-intensity reduction with high-frequency repetitive transcranial magnetic stimulation. This is a reasonable specialty-level option, with counseling that central-pain pharmacotherapies and stimulation strategies often provide partial rather than complete relief. Nature+1NatureTranscranial Magnetic Stimulation Applications in ...NatureNeuropathic pain | Nature Reviews Neurology

Invasive neurostimulation, including spinal cord stimulation, remains a last-resort approach in chronic neuropathic pain and is controversial in CPSP. Reserve evaluation for highly selected patients in experienced centers after diagnostic confirmation, rehabilitation optimization, and noninvasive options; patient selection should account for uncertain long-term benefit and procedural burden. NatureNatureNeuropathic pain | Nature Reviews Neurology

At medication initiation, define one or two measurable goals such as improved sleep continuity, increased therapy participation, more independent transfers, or tolerance of limb use. At each titration visit, document pain intensity, allodynia or cold sensitivity, daytime sedation, dizziness, edema, falls, mood, and sleep. This prevents escalation of a drug that lowers a numeric pain score without functional gain. PubMed+1PubMedCentral Post-Stroke Pain Syndrome - StatPearls - NCBI - NIHPubMedClinical use of pregabalin in the management of central neuropathic pain - PMC

Re-examine the affected limb when the phenotype changes. New edema, erythema, warmth, stiffness, or finger pain favors shoulder-hand syndrome; new pain with restricted passive range of motion or increased tone favors musculoskeletal or spasticity-related pathology. Redirect management to the new or coexisting diagnosis rather than simply increasing a central analgesic. AHA Journals+2AHA JournalsPrevalence, Trajectory, and Predictors of Poststroke PainWolters KluwerAcupuncture for shoulder-hand syndrome after stroke: An... : MedicinePubMedCentral Post-Stroke Pain Syndrome - StatPearls - NCBI - NIH

Use shared decisions when benefit is partial. Current pharmacologic options for CPSP have limited benefit overall, and the clinical target is meaningful reduction of disability and distress rather than complete analgesia. Patients with persistent functional impairment should remain connected to stroke rehabilitation and pain-focused follow-up while neuromodulation options are considered. Nature+1NatureNeuropathic pain | Nature Reviews NeurologyPubMedCentral Post-Stroke Pain Syndrome - StatPearls - NCBI - NIH